Your browser doesn't support javascript.
loading
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T-cell therapy.
Cao, Xing-Yu; Zhang, Jian-Ping; Lu, Yue; Zhao, Yan-Li; Liu, De-Yan; Xiong, Min; Sun, Rui-Juan; Wei, Zhi-Jie; Zhou, Jia-Rui; Zhang, Xian; Yang, Jun-Fang; Li, Jingjing; Lu, Peihua.
Afiliación
  • Cao XY; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Zhang JP; Beijing Lu Daopei Hospital, Beijing, China.
  • Lu Y; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Zhao YL; Beijing Lu Daopei Hospital, Beijing, China.
  • Liu DY; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Xiong M; Beijing Lu Daopei Hospital, Beijing, China.
  • Sun RJ; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Wei ZJ; Beijing Lu Daopei Hospital, Beijing, China.
  • Zhou JR; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Zhang X; Beijing Lu Daopei Hospital, Beijing, China.
  • Yang JF; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Li J; Beijing Lu Daopei Hospital, Beijing, China.
  • Lu P; Hebei Yanda Lu Daopei Hospital, Langfang, China.
Br J Haematol ; 204(6): 2351-2364, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38613241
ABSTRACT
CD7-targeted chimeric antigen receptor T-cell (CAR-T) therapy has shown promising initial complete remission (CR) rates in patients with refractory or relapsed (r/r) T-cell acute lymphoblastic leukaemia and lymphoblastic lymphoma (T-ALL/LBL). To enhance the remission duration, consolidation with allogeneic haematopoietic stem cell transplantation (allo-HSCT) is considered. Our study delved into the outcomes of 34 patients with r/r T-ALL/LBL who underwent allo-HSCT after achieving CR with autologous CD7 CAR-T therapy. These were compared with 124 consecutive T-ALL/LBL patients who received allo-HSCT in CR following chemotherapy. The study revealed that both the CAR-T and chemotherapy cohorts exhibited comparable 2-year overall survival (OS) (61.9% [95% CI, 44.1-78.1] vs. 67.6% [95% CI, 57.5-76.9], p = 0.210), leukaemia-free survival (LFS) (62.3% [95% CI, 44.6-78.4] vs. 62.0% [95% CI, 51.8-71.7], p = 0.548), non-relapse mortality (NRM) rates (32.0% [95% CI, 19.0-54.0] vs. 25.3% [95% CI, 17.9-35.8], p = 0.288) and relapse incidence rates (8.8% [95% CI, 3.0-26.0] vs. 15.8% [95% CI, 9.8-25.2], p = 0.557). Patients aged ≤14 in the CD7 CAR-T group achieved high 2-year OS and LFS rates of 87.5%. Our study indicates that CD7 CAR-T therapy followed by allo-HSCT is not only effective and safe for r/r T-ALL/LBL patients but also on par with the outcomes of those achieving CR through chemotherapy, without increasing NRM.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inducción de Remisión / Inmunoterapia Adoptiva / Trasplante de Células Madre Hematopoyéticas / Antígenos CD7 / Leucemia-Linfoma Linfoblástico de Células T Precursoras Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inducción de Remisión / Inmunoterapia Adoptiva / Trasplante de Células Madre Hematopoyéticas / Antígenos CD7 / Leucemia-Linfoma Linfoblástico de Células T Precursoras Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido